Wall Street analysts forecast that Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) will report earnings per share of ($0.87) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Anthera Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.71) and the lowest estimate coming in at ($1.03). Anthera Pharmaceuticals reported earnings per share of ($2.88) in the same quarter last year, which would suggest a positive year-over-year growth rate of 69.8%. The business is scheduled to report its next earnings report on Monday, February 26th.
On average, analysts expect that Anthera Pharmaceuticals will report full-year earnings of ($3.21) per share for the current fiscal year, with EPS estimates ranging from ($3.61) to ($2.95). For the next fiscal year, analysts expect that the company will report earnings of ($3.44) per share, with EPS estimates ranging from ($3.92) to ($2.68). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Anthera Pharmaceuticals.
Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.90) by $0.32. During the same quarter last year, the company earned ($4.85) earnings per share.
Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) opened at $1.91 on Friday. Anthera Pharmaceuticals has a one year low of $1.20 and a one year high of $20.24.
A number of institutional investors have recently added to or reduced their stakes in ANTH. Goldman Sachs Group Inc. raised its holdings in Anthera Pharmaceuticals by 1,376.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 335,595 shares during the period. UBS Group AG raised its holdings in Anthera Pharmaceuticals by 9.9% in the 1st quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 33,901 shares during the period. Finally, Wedbush Securities Inc. raised its holdings in Anthera Pharmaceuticals by 75.8% in the 3rd quarter. Wedbush Securities Inc. now owns 73,764 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 31,800 shares during the period. 16.24% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Zacks: Analysts Expect Anthera Pharmaceuticals, Inc. (ANTH) Will Post Earnings of -$0.87 Per Share” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/03/zacks-analysts-expect-anthera-pharmaceuticals-inc-anth-will-post-earnings-of-0-87-per-share.html.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.